Medicines and Healthcare products Regulatory Agency (MHRA) Guidance producer subject to accreditation. Process subject to accreditation
|
|
- Maximilian Fisher
- 6 years ago
- Views:
Transcription
1 Guidance producer subject to accreditation Process subject to accreditation Medicines and Healthcare products Regulatory Agency (MHRA) Device Bulletins Date: 18 June 2010 Draft Accreditation Report for consultation
2 Contents Introduction... 3 Accreditation recommendation... 3 Implementation... 4 Reapplication for accreditation... 5 Appendix A: NHS Evidence accreditation analysis... 7 Appendix B: Bibliography Appendix C: Advisory Committee members, external advisers and NHS Evidence accreditation team... 15
3 Introduction The NHS Evidence Accreditation Scheme recognises organisations that demonstrate high standards in producing health or social care guidance. Evidence users can therefore have high confidence in the quality of the information. Organisations can publicly display a seal of approval called an Accreditation Mark for three years after their processes have been accredited. The process for accrediting producers of guidance and recommendations for practice is described in the process manual 1. Accreditation recommendation It is proposed that the process to produce Device Bulletin (DB) guidance by the Medicines and Healthcare products Regulatory Agency (MHRA) Device Technology and Safety (DTS) Division is recommended for NHS Evidence accreditation. This draft decision is subject to public consultation before a final decision is made. Background to the guidance producer The MHRA was set up in April 2003 from a merger of the Medicines Control Agency and the Medical Devices Agency. The MHRA is an executive agency of the Department of Health (DH). The MHRA is the government agency responsible for ensuring that medicines and medical devices are effective and acceptably safe. The MHRA monitors the use of medicines and devices, and takes any necessary action to protect the public if there is a problem. The MHRA aims to make as much information as possible publicly available. Within the MHRA, the Device Technology and Safety (DT&S) division investigates adverse incidents involving medical devices reported by the NHS and private hospitals, C232A0-19B9-E0B5-D4A11FA899F4C219
4 care homes, manufacturers and directly from the public. Medical devices range from the most sophisticated diagnostic equipment used in hospitals, to simple bandages and other products sold over the counter to the public. Summary Device Bulletins provide safety information to medical device users, both professional and the public where applicable, to ensure they have the most up to date information. Device Bulletins contain guidance and information on aspects of general safe use and management of medical devices. They are written as a result of experience gained from adverse incident investigations, contacts with manufacturers and users, and other sources of information. The process used to produce Device Bulletins has a documented process for the evidence search that is fit for purpose and all evidence found is included for assessment. Suggestions to further strengthen the MHRA DT&S division development processes for Device Bulletins are: clarifying the role of lay members in the development process for Device Bulletins, including how the Public and patient engagement strategy is used clearly documenting, within the guidance, how the strength of the evidence base was assessed This draft decision is now going out for consultation, and the decision will be reviewed by the committee in the light of any feedback received before making a final recommendation. David Haslam Chair, Advisory Committee June 2010
5 Implementation If accreditation is awarded, guidance from the accredited producer will be identified on NHS Evidence by the Accreditation Mark. The accredited guidance producer is also granted a royalty-free, worldwide licence to use the NHS Evidence Accreditation Mark in accordance with the Conditions and Terms of Use 2. Providing these conditions are met, a guidance producer's accreditation will last for three years from publication of approval on the NHS Evidence website. Accredited guidance producers must take reasonable steps to ensure the accredited processes are followed when generating the type of evidence for which they are accredited. Accredited guidance producers should have quality assurance mechanisms in place and must inform NHS Evidence of any significant change to a process within 30 days. Figure: The NHS Evidence Accreditation Mark 2 D471CA81220F57DA
6 Reapplication for accreditation If accreditation is not granted, guidance from the non-accredited producer will still be available on the NHS Evidence site but will not be identified by the accreditation mark graphic. Guidance producers that are not accredited following the accreditation process have the opportunity to reapply from one year after the previous assessment. It is assumed that the organisation will have addressed any concerns highlighted in the original assessment before reapplying. The NHS Evidence team will provide detailed feedback and advice on areas where improvement is required to meet the criteria in a future application.
7 Appendix A: NHS Evidence accreditation analysis The Advisory Committee considered the following analysis of the guidance producer s compliance with NHS Evidence accreditation criteria, which covers six discrete domains. The full analysis leading to the accreditation decision is shown below. Domain Criterion Evidence for meeting the criterion Accreditation decision Does the guidance producer have a policy in place and adhered to that requires them to explicitly detail: 1.1 Overall objective The overall objective is Safeguarding public health and is documented on the front cover of all guidance documents reviewed. Scope and purpose 1.2 The clinical, healthcare or social questions covered In the case of Device Bulletins b-f the questions are safety based. All examples of guidance reviewed showed the safety questions as numbered sections in the body of the guidance documents. The questions are clearly indicated and, where applicable, explained. 1.3 Population and/or target audience to whom the guidance applies The Advisory Notice a section 2.2 states that inclusion of the target audience when drafting a proposal provides some evidence of need of the Device Bulletin. In the example guidance documents b-f, patient population can be inferred from the titles.
8 Domain Criterion Evidence for meeting the criterion Accreditation decision 1.4 Guidance includes clear recommendations in reference to specific clinical, healthcare or social circumstances The Advisory Notice a section 1 documents how the process of defining the information and considerations of specific sections take place. Evidence of this process in practice is clear in all of the examples of guidance b-f reviewed. Does the guidance producer have a policy in place and adhered to that means it includes: Stakeholder involvement 2.1 Individuals from all relevant stakeholder groups, including patient groups, in developing guidance 2.2 Patient and service user representatives and seeks patients views and preferences in developing guidance 2.3 Representative intended users in developing guidance. The composition of both the drafting group and the MHRA s Committee for the Safety of Devices (CSD) show that all relevant stakeholder groups are involved in developing guidance. The CSD includes patient representatives. Public and patient engagement strategy is available on the website which further seeks the views of patients and patient representatives. Section 2.4 of the Advisory Notice a specifies that the review group should always include a typical reader. In addition the Advisory Notice also states that any relevant professional bodies should be included in the review process. Rigour of Does the guidance producer have a clear policy in place that:
9 Domain Criterion Evidence for meeting the criterion Accreditation decision development 3.1 Requires the guidance producer to use systematic methods to search for evidence and provide details of the search strategy 3.2 Requires the guidance producers to state the criteria and reasons for inclusion or exclusion of evidence identified by the evidence review 3.3 Describes the strengths and limitations of the body of evidence and acknowledges any areas of uncertainty Typical evidence searched includes trends in medical device incidents reported to MHRA (via adverse incidents tracking database) and data from registries or clinical studies. Systematic methods are used to search for evidence on which the Device Bulletin is based. No evidence is excluded from searches to produce a Device Bulletin,. All information found by the search strategy is included. The adverse incidents reports database is searched to provide the evidence base for the Device Bulletins. All of the information found during a specific search is used and no weighting is applied, which is fit for purposed for this type of guidance product. 3.4 Describes the method used to arrive at recommendations (for example, a voting system or formal consensus techniques like Delphi consensus) The process for the production of Device Bulletins is an authorship process, and therefore no voting occurs. However the guidance development process contains a clear description of the method used to develop recommendations.
10 Domain Criterion Evidence for meeting the criterion Accreditation decision 3.5 Requires the guidance producers to consider the health benefits against the side effects and risks in formulating recommendations This is the overall objective of the MHRA and the balance between risks and benefits is shown in the Aims and objectives section of their website. The principal aim of the guidance product is to balance health benefits against risks by providing healthcare professionals with up-to-date medical device safety information so that they can make informed choices. 3.6 Describes the processes of external peer review Section 2.4 and 4.3 of the Advisory Notice a outlines the process for external peer review of Device Bulletins. 3.7 Describes the process of updating guidance and maintaining and improving guidance quality Device Bulletins provide safety advice driven by new findings regarding possible safety issues for medical devices. Rather than being date driven the guidance is data driven so no regular updating schedule is available. Furthermore, the guidance itself is an update that may contain important ancillary information which is provided in addition to that produced when the medical device is licensed for production. Does the guidance producer ensure that: Clarity and presentation 4.1 Recommendations are specific, unambiguous and clearly identifiable Device Bulletins provide advice on the safe use of medical devices and additional up-to-date safety information to medical device users. The safety recommendations are specific, unambiguous and clearly shown within the Device Bulletins.
11 Domain Criterion Evidence for meeting the criterion Accreditation decision 4.2 Different options for the management of the condition or options for intervention are clearly presented 4.3 The date of search, the date of publication or last update and the proposed date for review are clearly stated This criterion is not applicable because Device Bulletin advise on the safe use of specific devices, not the management of conditions.. All example guidance b-f reviewed bears the date of publication and date of update where applicable. The date of literature search cannot be found. The guidance is eventrather than date-led since the updates are driven by new evidence so review dates are not applicable (see also criterion 3.1). Not applicable 4.4 The content of the guidance is suitable for the specified target audience. If patients or service users are part of this audience, the language should be appropriate. The guidance examples b-f reviewed are suitable for all audiences. Any technical terms are explained and ideas are described so the reader can understand the options (where applicable), recommendations and the evidence behind them. Does the guidance producer routinely consider: Applicability 5.1 Publishing support tools to aid implementation of guidance An alert process ensures that this guidance reaches its target audience. Since the guidance is a dissemination of safety information from the MHRA s DT&S division it describes how to use a medical device with a revised safety review and is considered obligatory.
12 Domain Criterion Evidence for meeting the criterion Accreditation decision 5.2 Discussion of potential organisational and financial barriers in applying its recommendations 5.3 That their guidance is current, with review criteria for monitoring and/or audit purposes within each product This criterion is not applicable because external organisations must overcome financial and organisational barriers to implement the guidance for safe use of medical devices. This criterion is not applicable for this type of guidance product. A date of publication is stated but no evidence of a process for review criteria, audit or information about monitoring is provided (see criterion 5.2). It would not be productive to measure compliance with only those aspects of safety Not applicable Not applicable contained within the guidance b-f. Does the guidance producer: 6.1 Ensure editorial independence from the funding body Section 5 MHRA framework document details the process of how the funding is collated and disseminated. In addition to the dispersed funding mechanism, the guidance is developed via a number of multidisciplinary Editorial groups, such as the CSD and it is peer reviewed. independence 6.2 Demonstrate transparency about the funding mechanisms for its guidance The MHRA is an executive agency of the DH with trading fund status. The agency is funded by fees charged for fulfilment of statutory obligations, charges for non-statutory services and the DH. Section 5 (Finance) of the MHRA framework document describes how the MHRA generates and disseminates its finances and explains its accounting and auditing arrangements.
13 Domain Criterion Evidence for meeting the criterion Accreditation decision 6.3 Record and state any potential conflicts of interest of individuals involved in developing the recommendations 6.4 Take account of any potential for bias in the conclusions or recommendations of the guidance Section 7.14 of the MHRA framework document states that all MHRA employees are required to state any potential conflicts of interest. Any declarations of interests are published on the website. A combination of conflict of interest declarations, guidance decisions determined by multidisciplinary groups, peer review and transparency in the way the work is funded ensures this criterion is satisfied. The webpage What principles inform the decisions? point 10 also documents the agency s decisions will as far as possible be transparent and open to public scrutiny; a reasonable person reviewing our decisions should understand the rationale. a Advisory Notice Drafting and publishing a device bulletin, 2002 (process manual). b DB2009 (02) Adverse incident reports 2008 c DB2008 (04) In vitro diagnostic medical devices used in combination d DB2008 (03) Guidance on the safe use of lasers, intense light source systems and LEDs in medical, surgical and aesthetic practises e DB2009 (01) Reporting adverse incidents and disseminating medical device alerts f DB2007 (03) Safety guidelines for magnetic resonance imaging equipment in clinical use.
14 Appendix B: Bibliography Appendix B lists the additional information taken into account in the analysis and considered by the Committee. Document name Description Location DB2009 (02) Adverse Example guidance incident reports 2008 supplied by guidance producer DB2008 (04) In vitro Example guidance diagnostic medical devices supplied by guidance used in combination producer DB2008 (03) Guidance on Example guidance the safe use of lasers, supplied by guidance intense light source producer systems and LED s in medical, surgical and aesthetic practises. guidance/devicebulletins/con guidance/devicebulletins/con guidance/devicebulletins/con DB2009 (01) Reporting Adverse incidents and disseminating Medical Device Alerts DB2007 (03) Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical Use ADVISORY NOTICES: Drafting and publishing a Device Bulletin MHRA Framework document Example guidance chosen arbitrarily to validate the application of processes Example guidance chosen arbitrarily to validate the application of processes Drafting Device Bulletins procedure Document outlining the MHRA framework guidance/devicebulletins/con guidance/devicebulletins/con Drafting Device Bulletins procedure Searchresults/CON008369
15 Appendix C: Advisory Committee members, external advisers and NHS Evidence accreditation team NHS Evidence Advisory Committee Members The NHS Evidence Advisory Committee operates as a standing advisory committee of the Board of the National Institute for Health and Clinical Excellence (NICE). The Committee provides advice to the Institute on a framework for accrediting sources of evidence that should be recognised as trusted sources of information for the NHS. The Chair of the Committee is appointed by the Institute s Board and the meetings are conducted by the Chair or in his/her absence the vice chair. The current Chair is David Haslam. A full list of the Advisory Committee membership is available on the NICE website 3. The members have been appointed for a period of 18 months. This may be extended by mutual agreement to a further term of 3 years and up to a maximum term of office of 10 years. The decisions of the Committee are arrived at by a consensus of those members present. The quorum is set at 50% of committee membership. The Committee submits its recommendations to the Institute s Guidance executive which acts under delegated powers of the Institute s Board in considering and approving its recommendations. Committee members are asked to declare any interests in the guidance producer to be accredited. If it is considered that there is a conflict of interest, the member(s) is excluded from participating further in the discussions. A list of the committee members who took part in the discussions for this accreditation decision appears below. Title Name Surname Role Organisation Ms Judy Birch Lay member 3 Medicines and Healthcare products Regulatory Agency: Device Technology and Safety Division; Device Bulletins: Draft Accreditation Report Page 15 of 17
16 Mr Richard Brownhill Clinical Development & Nurse practitioner Calderdale and Huddersfield NHS Trust and Kirklees PCT Ms Amanda Edwards Head of Knowledge Services Social Care Institute for Excellence (SCIE) Ms Joyce Epstein Lay member Dr Brian Fisher General Practitioner NHS Alliance (GP and national patient/public lead) Professor David Haslam National Clinical Advisor Care Quality Commission Dr Bobbie Jacobson Dr Monica Lakhanpaul Professor Stuart Logan Dr Donal O Donoghue Professor Sandy Oliver Dr Mahendra Patel Director of London Health Observatory, Vice Chair of Association of PH Observatories Senior Lecturer / Consultant Paediatrician / Clinical Director Professor of Paediatric Epidemiology National Clinical Director for Kidney Care and consultant renal physician Professor of Public Policy, Deputy Director, Social Science Research Unit Senior lecturer in pharmacy practice, school of applied sciences/consultant Pharmacist London Health Observatory Health Education Research and Development Unit (HERADU), Department of Medical Education and Social Care, University of Leicester Peninsula College of Medicine and Dentistry Salford Royal NHS Foundation Trust Cochrane Consumers and Communication Review Group, University of London University of Huddersfield Mr Adrian Reyes- Hughes Associate Clinical Director NHS Direct Dr Karen Ritchie Ms Sasha Shepperd Dr Mark Strong Lead Health Services Researcher Senior Research Scientist, Department of Public Health MRC Fellow, Section of Public Health NHS Quality Improvement Scotland University of Oxford School of Health and Related Research (ScHARR) Medicines and Healthcare products Regulatory Agency: Device Technology and Safety Division; Device Bulletins: Draft Accreditation Report Page 16 of 17
17 University of Sheffield Ms Gill Swash Head of knowledge and Library Services NHS Western Cheshire Dr Sara Twaddle Director Scottish Intercollegiate Guidelines Network Advisory Committee Deputies Title Name Surname Role Organisation Deputising for Ms Lynda Cox Head of Knowledge Sharing and Learning North East Strategic Health Authority Stephen Singleton External Advisers for MHRA Device Technology and Safety Division Device Bulletins accreditation application Aideen Mary Tarpey, Epilepsy Specialist Nurse - Dorset, Poole Hospital NHS Foundation Trust, Poole, Dorset, UK Dr Timothy E Bates, Chief Scientific Officer, New-Use Therapeutics Limited, Nottingham, UK NHS Evidence accreditation team for MHRA Device Technology and Safety Division Device Bulletins accreditation application Stephanie Birtles, Accreditation Technical Analyst, NHS Evidence, National Institute for Health and Clinical Excellence, Manchester, UK Dr Paul Chrisp, Associate Director Accreditation, NHS Evidence, National Institute for Health and Clinical Excellence, Manchester, UK Medicines and Healthcare products Regulatory Agency: Device Technology and Safety Division; Device Bulletins: Draft Accreditation Report Page 17 of 17
Final Accreditation Report
Guidance producer: Medicines and Healthcare products Regulatory Agency (MHRA) Guidance product: Device Bulletins Date: 20 September 2010 Final Accreditation Report Page 1 of 21 Contents Introduction...
More informationMedicines and Healthcare products Regulatory Agency (MHRA) Guidance producer subject to accreditation. Process subject to accreditation
Guidance producer subject to accreditation Process subject to accreditation Medicines and Healthcare products Regulatory Agency (MHRA) Pharmacovigilance Public Assessment Reports Date: 18 June 2010 Draft
More informationMedicines and Healthcare products Regulatory Agency (MHRA) Public Assessment Reports
Guidance producer: Medicines and Healthcare products Regulatory Agency (MHRA) Guidance product: Public Assessment Reports Date: 18 June 2010 Version: 1.4 Draft Accreditation Report for consultation Medicines
More informationFinal Accreditation Report
Guidance producer: Royal College of Surgeons of England: Surgical Specialty Associations Guidance product: Clinical Commissioning Guides Date: 28 February 2013 Version: 1.3 Final Accreditation Report Royal
More informationEgton Medical Information Systems Limited (EMIS) Clinical Immediate Reference articles
Guidance producer: Egton Medical Information Systems Limited (EMIS) Guidance product: Clinical Immediate Reference articles Date: 17 August 2010 Final Accreditation Report Contents Introduction... 3 Accreditation
More informationFinal Accreditation Report
Guidance producer: Resuscitation Council (UK) Guidance product: 2010 resuscitation guidelines Date: 2 August 2012 Version: 1.4 Final Accreditation Report Page 1 of 19 Contents Introduction... 3 Accreditation
More informationFinal Accreditation Report
Guidance producer: Healthcare Infection Society Guidance product: Clinical Guidelines Date: 23 March 2015 Version: 1.6 Final Accreditation Report Page 1 of 19 Contents Introduction... 3 Accreditation recommendation...
More informationClinical guideline for the prevention and treatment of osteoporosis
Guidance producer: National Osteoporosis Guideline Group Guidance product: Clinical guideline for the prevention and treatment of osteoporosis Date: 9 March 2017 Version: 1.3 Final Accreditation Report
More informationThe Renal Association
Guidance producer: The Renal Association Guidance product: Clinical Practice Guidelines Date: 11 January 2017 Version: 1.4 Final Accreditation Report Contents Introduction... 3 Accreditation recommendation...
More informationDraft Accreditation Report for consultation
Guidance producer: Guidance product: NHS Fetal Anomaly Screening Programme (FASP) UK National Screening Committee (NSC) NHS Fetal Anomaly Screening Programme Screening for Down s syndrome: UK NSC Policy
More informationBritish Association of Dermatologists
Guidance producer: British Association of Dermatologists Guidance product: Service Guidance and Standards Date: 13 March 2017 Version: 1.2 Final Accreditation Report Page 1 of 26 Contents Introduction...
More informationFinal Accreditation Report
Guidance producer: British National Formulary Publications Guidance product: Nurse Prescribers Formulary Date: 10 March 2014 Final Accreditation Report Page 1 of 28 Contents Introduction... 3 Accreditation
More informationFinal Accreditation Report
Guidance producer: The Royal College of Physicians of London Guidance product: National Clinical Guideline for Stroke Date: 19 September 2016 Version: 1.2 Final Accreditation Report Report Page 1 of 21
More informationFinal Accreditation Report - for guidance and advice for use in decision support systems
Guidance producer: NHS Direct Guidance product: The content of the Call Streaming Prioritisation Tool and Teleguides Date: 2 January 2013 Version: 1.4 Final Accreditation Report - for guidance and advice
More informationAccreditation Decision Report for consultation
Guidance producer: British National Formulary Publications Guidance product: British National Formulary, British National Formulary for Children Date: 29 August 2013 Version: 1.4 Accreditation Decision
More informationProcess and methods Published: 23 January 2017 nice.org.uk/process/pmg31
Evidence summaries: process guide Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationBritish Society for Surgery of the Hand. (BSSH) Evidence for Surgical
British Society for Surgery of the Hand (BSSH) Evidence for Surgical Treatment (B.E.S.T.) Process Manual 1 st Edition (12 th version, November 2016) Review Date: November 2019 BSSH Evidence for Surgical
More informationClinical Practice Guideline Development Manual
Clinical Practice Guideline Development Manual Publication Date: September 2016 Review Date: September 2021 Table of Contents 1. Background... 3 2. NICE accreditation... 3 3. Patient Involvement... 3 4.
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Principles Interim Process and Methods of the Highly Specialised Technologies Programme 1. Our guidance production processes are based on key principles,
More informationHow NICE clinical guidelines are developed
Issue date: January 2009 How NICE clinical guidelines are developed: an overview for stakeholders, the public and the NHS Fourth edition : an overview for stakeholders, the public and the NHS Fourth edition
More informationCOMMISSIONING SUPPORT PROGRAMME. Standard operating procedure
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE COMMISSIONING SUPPORT PROGRAMME Standard operating procedure April 2018 1. Introduction The Commissioning Support Programme (CSP) at NICE supports the
More informationNHS. The guideline development process: an overview for stakeholders, the public and the NHS. National Institute for Health and Clinical Excellence
NHS National Institute for Health and Clinical Excellence Issue date: April 2007 The guideline development process: an overview for stakeholders, the public and the NHS Third edition The guideline development
More informationDraft National Quality Assurance Criteria for Clinical Guidelines
Draft National Quality Assurance Criteria for Clinical Guidelines Consultation document July 2011 1 About the The is the independent Authority established to drive continuous improvement in Ireland s health
More informationQUALITY COMMITTEE. Terms of Reference
QUALITY COMMITTEE Terms of Reference CONSTITUTION 1. The Board of Directors approved the establishment of the Quality Committee (known as the Committee in these terms of reference) for the purpose of:
More informationEuropean Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications
European Reference Networks Guidance on the recognition of Healthcare Providers and UK Oversight of Applications NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients
More informationInitial education and training of pharmacy technicians: draft evidence framework
Initial education and training of pharmacy technicians: draft evidence framework October 2017 About this document This document should be read alongside the standards for the initial education and training
More informationVaccine uptake in under 19s (quality standard) Stakeholders Action on Smoking & Health (ASH) Advertising Standards Authority Advertising Standards
Vaccine uptake in under 19s (quality standard) Stakeholders Action on Smoking & Health (ASH) Advertising Standards Authority Advertising Standards Authority (ASA) Alcohol Concern Anglian Community Enterprise
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health and Social Care Directorate Quality standards Process guide
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and Social Care Directorate Quality standards Process guide December 2014 Quality standards process guide Page 1 of 44 About this guide This guide
More informationCLINICAL GOVERNANCE AND QUALITY COMMITTEE. Final - Terms of Reference - Final
CLINICAL GOVERNANCE AND QUALITY COMMITTEE Final - Terms of Reference - Final CONSTITUTION 1. The Board of Directors approved the establishment of the Clinical Governance and Quality Committee (known as
More informationEuropean network of paediatric research (EnprEMA)
17 February 2012 EMA/77450/2012 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationIndependent prescribing conversion programme. De Montfort University Report of a reaccreditation event May 2017
Independent prescribing conversion programme De Montfort University Report of a reaccreditation event May 2017 GPhC, independent prescribing conversion programme reaccreditation report Page 1 of 10 Event
More informationPublic Health Skills and Career Framework Multidisciplinary/multi-agency/multi-professional. April 2008 (updated March 2009)
Public Health Skills and Multidisciplinary/multi-agency/multi-professional April 2008 (updated March 2009) Welcome to the Public Health Skills and I am delighted to launch the UK-wide Public Health Skills
More informationCCG Policy for Working with the Pharmaceutical Industry
CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry
More informationCORRESPONDING AUTHOR:
TITLE: A paediatrician s guide to Clinical Trials Units AUTHORS: Chris Gale, Edmund Juszczak CORRESPONDING AUTHOR: Dr C Gale, NIHR Clinical Trials Fellow, Imperial Clinical Trials Unit and section of Neonatal
More informationMaximising the impact of nursing research. RCN research conference 5-7 April 2017, Oxford, UK
Maximising the impact of nursing research RCN research conference 5-7 April 2017, Oxford, UK Paper 1 Maximising the Impact of nursing research through collaboration Professor Daniel Kelly, RCN Professor
More informationabcdefghijklmnopqrstu
Healthcare Policy and Strategy Directorate Quality Division Dear Colleague INTRODUCTION AND AVAILABILITY OF NEWLY LICENSED MEDICINES IN THE NHS IN SCOTLAND Dear Colleague This guidance sets out the policy
More informationSPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY
SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with
More informationCentral Alerting System (CAS) Policy
Document Title Reference Number Lead Officer Author(s) (name and designation) Ratified By Central Alerting System (CAS) Policy NTW(O)17 Gary O Hare Executive Director of Nursing and Operations Tony Gray
More informationUnlicensed Medicines Policy
Unlicensed Medicines Policy This procedural document supersedes: PAT/MM 4 v.3 Policy and Procedure for the Use of Unlicensed Medicines Did you print this document yourself? The Trust discourages the retention
More information5.3: POLICY FOR THE MANAGEMENT OF REQUESTS FOR MEDICINES VIA PEER APPROVED CLINICAL SYSTEM (PACS) TIER 2
NHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 5: NON-FORMULARY PROCESSES 5.3: POLICY FOR THE MANAGEMENT OF REQUESTS FOR MEDICINES VIA PEER APPROVED CLINICAL SYSTEM
More informationPROGRAMME SPECIFICATION(POSTGRADUATE) 1. INTENDED AWARD 2. Award 3. Title 28-APR NOV-17 4
Status Approved PROGRAMME SPECIFICATION(POSTGRADUATE) 1. INTENDED AWARD 2. Award 3. MSc Surgical Care Practice (Trauma & Orthopaedics) 4. DATE OF VALIDATION Date of most recent modification (Faculty/ADQU
More informationERN Assessment Manual for Applicants
Share. Care. Cure. ERN Assessment Manual for Applicants 3.- Operational Criteria for the Assessment of Networks An initiative of the Version 1.1 April 2016 History of changes Version Date Change Page 1.0
More informationPolicy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry
Policy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry March 2017 NOTE: This policy will be subject to review in 2017/18 as part of the partnership work between North
More informationSupporting information for appraisal and revalidation: guidance for Occupational Medicine, June 2014
Supporting information for appraisal and revalidation: guidance for Occupational Medicine, June 2014 Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction
More informationSupporting information for appraisal and revalidation: guidance for Occupational Medicine, April 2013
Supporting information for appraisal and revalidation: guidance for Occupational Medicine, April 2013 Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction
More informationNICE Charter Who we are and what we do
NICE Charter 2017 Who we are and what we do 1. The National Institute for Health and Care Excellence (NICE) is the independent organisation responsible for providing evidence-based guidance on health and
More informationStandards for Registered Pharmacies
Council meeting 13 September 2012 Public business Standards for Registered Pharmacies Purpose This paper seeks the Council s approval of the standards for registered pharmacies. The Council is asked to
More informationConsultation on initial education and training standards for pharmacy technicians. December 2016
Consultation on initial education and training standards for pharmacy technicians December 2016 The text of this document (but not the logo and branding) may be reproduced free of charge in any format
More informationMHRA response to the Independent Review on access to clinical advice and engagement with the clinical community in relation to medical devices
MHRA response to the Independent Review on access to clinical advice and engagement with the clinical community in relation to medical devices The MHRA warmly welcomes the independent report Expert Clinical
More informationMembership of Oral health for adults in care homes public health advisory committee
Committee membership list Oral health for adults in care homes guideline Committee Membership of Oral health for adults in care homes public health advisory committee The Committee will operate as an advisory
More informationCLINICAL GOVERNANCE AND QUALITY COMMITTEE Terms of Reference
CLINICAL GOVERNANCE AND QUALITY COMMITTEE Terms of Reference CONSTITUTION 1. The Board of Directors approved the establishment of the Clinical Governance and Quality Committee (known as the Committee in
More informationEUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS)
EUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS) 31 January 2013 1 EUCERD RECOMMENDATIONS ON RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS) INTRODUCTION 1. BACKGROUND TO
More informationWORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0
WORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0 1 Standard Operating Procedure St Helens CCG Working with The Pharmaceutical Industry Policy Version 1.0 Implementation Date May 2017 Review
More informationNHS QIS & NICE Advice. defi nitions & status
NHS QIS & NICE Advice defi nitions & status NHS Quality Improvement Scotland 2006 First published August 2006 You can copy or reproduce the information in this document for use within NHSScotland and for
More informationNorth East Hampshire and Farnham Clinical Commissioning Group Safeguarding Framework
North East Hampshire and Farnham Clinical Commissioning Group Safeguarding Framework North East Hampshire and Farnham Clinical Commissioning Group Safeguarding Strategic Framework Page 3 of 27 Contents
More informationCourse of Study for the Certification of Competence in Administering Intravenous Injections
R A D I O G R A P H Y Course of Study for the Certification of Competence in Administering Intravenous Injections 1 2 Course of Study for the Certification of Competence in Administering Intravenous Injections
More informationReport of a Scoping Exercise for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO)
Continuity of Care Report of a Scoping Exercise for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO) Summer 2000 prepared by George Freeman and Sasha Shepperd
More informationStandards for the initial education and training of pharmacy technicians. October 2017
Standards for the initial education and training of pharmacy technicians October 2017 The text of this document (but not the logo and branding) may be reproduced free of charge in any format or medium,
More informationYorkhill Children s Charity Research Strategy
Yorkhill Children s Charity Research Strategy 1. Objectives Yorkhill Children s Charity provides and supports excellence in paediatric, obstetric and neonatal healthcare enhancing the treatment, care and
More informationUncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES
Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE SECTION 9(a) UNLICENSED MEDICINES BACKGROUND and PURPOSE Under the Medicines Act 1968 (EEC Directive 65/65), a company
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationProcess and methods Published: 30 November 2012 nice.org.uk/process/pmg6
The guidelines manual Process and methods Published: 30 November 2012 nice.org.uk/process/pmg6 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK
PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK 0 CONTENTS Course Description Period of Learning in Practice Summary of Competencies Guide to Assessing Competencies Page 2 3 10 14 Course
More informationFoundation in Paediatric Pharmaceutical Care 5th International Masterclass
Leading the field in paediatric courses for pharmacists Foundation in Paediatric Pharmaceutical Care 5th International Masterclass 15-17 October 2015 Evelina London Children s Hospital Guy s and St Thomas
More informationSection 2: Advanced level nursing practice competencies
Advanced Level Nursing Practice Section 2: Advanced level nursing practice competencies RCN Standards for advanced level nursing practice, advanced nurse practitioners, RCN accreditation and RCN credentialing
More informationIssue date: October Guide to the multiple technology appraisal process
Issue date: October 2009 Guide to the multiple technology appraisal process Guide to the multiple technology appraisal process Issued: October 2009 This document is one of a series describing the processes
More informationNational Institute for Health and Clinical Excellence. The guidelines manual
National Institute for Health and Clinical Excellence The guidelines manual January 2009 The guidelines manual About this document This document describes the methods used in the development of NICE guidelines.
More informationQuality and Safety Committee Terms of Reference
Approved May 2016 Quality and Safety Committee Terms of Reference 1. Constitution The Quality and Safety Committee is established as a sub-committee of The Hillingdon Hospitals NHS Foundation Trust (THH)
More informationEducation and Training Committee, 5 June 2014
Education and Training Committee, 5 June 2014 Directive 2013/55/EU the revised Recognition of Professional Qualifications (RPQ) Directive challenges and opportunities for the Health and Care Professions
More informationMEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY
MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY NHS employees and contractors link with the pharmaceutical industry in a number of ways, as a source of information, through the receipt
More informationGUIDANCE ON SUPPORTING INFORMATION FOR REVALIDATION FOR SURGERY
ON SUPPORTING INFORMATION FOR REVALIDATION FOR SURGERY Based on the Academy of Medical Royal Colleges and Faculties Core Guidance for all doctors GENERAL INTRODUCTION JUNE 2012 The purpose of revalidation
More informationALLOCATION OF RESOURCES POLICY FOR CONTINUING HEALTHCARE FUNDED INDIVIDUALS
ALLOCATION OF RESOURCES POLICY FOR CONTINUING HEALTHCARE FUNDED INDIVIDUALS APPROVED BY: South Gloucestershire Clinical Commissioning Group Quality and Governance Committee DATE Date of Issue:- Version
More informationPOLICY ON THE IMPLEMENTATION OF NICE GUID ANCE
POLICY ON THE IMPLEMENTATION OF NICE GUID ANCE Document Type Corporate Policy Unique Identifier CO-019 Document Purpose To outline the process for the implementation and compliance with NICE guidance and
More informationMedical Devices Management Policy
Document Author Written By: Medical Devices Co-ordinator Date: 07/02/17 Lead Director: Exectuve Director of Nursing & Quality Authorised Authorised By: Chief Executive Date: 11/04/2017 Effective Date:
More informationSupporting information for appraisal and revalidation: guidance for psychiatry
Supporting information for appraisal and revalidation: guidance for psychiatry Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction The purpose of revalidation
More informationDocument Title: Document Number:
including Document Title: Document Number: Version: 2.0 Ratified by: Committee Date ratified: 25/01/2018 Name of originator/author: Directorate: Department: Name of responsible individual: Rachel Fay Corporate
More informationHealth Research 2017 Call for Proposals. Evaluation process guide
Health Research 2017 Call for Proposals Evaluation process guide Evaluation process guide Health Research 2017 Call for Proposals la Caixa Foundation 0 0 Introduction This guide sets out the procedure
More informationSection Title. Prescribing competency framework Catherine Picton, Lead author
Prescribing competency framework Catherine Picton, Lead author What is in this presentation Context Uses of the competency framework Scope of the updated prescribing competency framework Introduction to
More informationIndependent Group Advising (NHS Digital) on the Release of Data (IGARD)
Document filename: Independent Group Advising (NHS Digital) on the Release of Data (IGARD) Directorate / Programme IGSA Project IGARD Document Reference Status Final Owner Martin Severs Version 1.6 Author
More informationFoundation in Paediatric Pharmaceutical Care 6th International Masterclass
Leading the field in paediatric courses Foundation in Paediatric Pharmaceutical Care 6th International Masterclass London, UK Sponsored by In collaboration with 1 Course details Dates Venues: Day 1: Thursday
More informationAre you responding as an individual or on behalf of an organisation?
Response form Address: 407 St John Street, London, EC1V 4AD Are you responding as an individual or on behalf of an organisation? If as an individual, are you responding as: a) a doctor? b) a patient? c)
More informationCouncil, 25 September 2014
Council, 25 September 2014 Directive 2013/55/EU the revised Recognition of Professional Qualifications (RPQ) Directive challenges and opportunities for the Health and Care Professions Council (HCPC) Executive
More informationNHS Lanarkshire Policy for the Availability of Unlicensed Medicines
NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:
More informationReview Date: 6/22/17. Page 1 of 5
Subject: Evaluation of New and Existing Technologies (UM 10) Original Effective Date: 4/24/07 Molina Clinical Policy (MCP)Number: Revision Date(s): 11/20/08, 1/28,09,1/14/10,3/11/10, MCP-000 2/10/2011,
More informationClinical Development Process 2017
InterQual Clinical Development Process 2017 InterQual Overview Thousands of people in hospitals, health plans, and government agencies use InterQual evidence-based clinical decision support content to
More informationSupporting information for appraisal and revalidation: guidance for pharmaceutical medicine
Supporting information for appraisal and revalidation: guidance for pharmaceutical medicine Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction The purpose
More informationG-I-N 2016 conference report
G-I-N 2016 conference report Olena Lishchyshyna was one of the 2016 LMIC conference participation support grant recipients. Below is an account of her experience at G-I-N 2016 and what she gained from
More informationConsultation on developing our approach to regulating registered pharmacies
Consultation on developing our approach to regulating registered pharmacies May 2018 The text of this document (but not the logo and branding) may be reproduced free of charge in any format or medium,
More informationAll areas of the Trust All Trust staff All Patients Deputy Chief Nurse & Chief Pharmacist Final
Trust Policy and Procedure Document Ref. No: PP(15)233 Non-Medical Prescribing Policy For use in: For use by: For use for: Document owner: Status: All areas of the Trust All Trust staff All Patients Deputy
More informationLeadership and management for all doctors
Leadership and management for all doctors The duties of a doctor registered with the General Medical Council Patients must be able to trust doctors with their lives and health. To justify that trust you
More informationDocument Details Clinical Audit Policy
Title Document Details Clinical Audit Policy Trust Ref No 1538-31104 Main points this document covers This policy details the responsibilities and processes associated with the Clinical Audit process within
More informationBritish Cardiovascular Society. Revalidation of cardiologists: Standards and Content of a portfolio for revalidation
Page 1 of 8 British Cardiovascular Society Revalidation of cardiologists: Standards and Content of a portfolio for revalidation David Hackett Vice-President, Clinical Standards Division August 2009 Introduction:
More informationDriving and Supporting Improvement in Primary Care
Driving and Supporting Improvement in Primary Care 2016 2020 www.healthcareimprovementscotland.org Healthcare Improvement Scotland 2016 First published December 2016 The publication is copyright to Healthcare
More informationImplementation of the right to access services within maximum waiting times
Implementation of the right to access services within maximum waiting times Guidance for strategic health authorities, primary care trusts and providers DH INFORMATION READER BOX Policy HR / Workforce
More informationEUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES
EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES 24 OCTOBER 2011 INTRODUCTION 1. THE EUROPEAN CONTEXT Centres of expertise (CE) and European Reference
More informationNHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION)
SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION) CONTENTS POLICY SUMMARY... 2 1. SCOPE... 4 2. AIM... 4 3. BACKGROUND... 4 4. POLICY STATEMENTS... 5 4.1. GENERAL STATEMENTS... 5 4.2 UNLICENSED
More informationMembership of Alcohol use disorders clinical guideline updates standing committee
Membership of Alcohol use disorders clinical guideline updates standing committee The Committee will operate as an advisory Committee to NICE s Board, developing clinical guideline updates. The terms of
More informationScottish Medicines Consortium. A Guide for Patient Group Partners
Scottish Medicines Consortium Advising on new medicines for Scotland www.scottishmedicines.org page 1 Acknowledgements Some of the information in this booklet is adapted from guidance produced by the HTAi
More informationNHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF
NHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF This guidance relates to all staff employed by NHS Fife (including staff within the Health &
More informationImproving the quality of diagnostic spirometry in adults: the National Register of certified professionals and operators
Improving the quality of diagnostic spirometry in adults: the National Register of certified professionals and operators September 2016 Improving the quality of diagnostic spirometry in adults: the National
More information